Clinical contraindications to allergen immunotherapy


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

It presents an analysis of international position papers, federal clinical recommendations and national publications focused on contraindications to allergen immunotherapy (AIT) in recent years. In details absolute and relative clinical contraindications to allergen immunotherapy (AIT) are described.

作者简介

O Kurbacheva

Institute of Immunology

Email: kurbacheva@gmail.com

K Pavlova

Institute of Immunology

M Galitskaya

Institute of Immunology

参考

  1. http://ec.europa.eu/health/files/eudralex/vol2/c/smpc_ guideline_rev2_en.pdf (assessed 2 April 2015).
  2. Pesek R.D., Lockey R.F. Treatment of Hymenoptera venom allergy: an update. Curr. Opin. Allergy Clin. Immunol. 2014, v. 14, p. 340-346.
  3. Cox L., Nelson H., Lockey R. et al. Allergen immunotherapy: a practice parameter third update. J. Allergy Clin. Immunol. 2011, v. 127, p. 1-55.
  4. Alvarez-Cuesta E., Bousquet J., Canonica G.W et al. EAACI, Immunotherapy Task Force. Standards for practical allergen-specific immunotherapy. J. Allergy. 2006, v. 61, p. 1-20.
  5. Krishna M.T., Ewan P.W., Diwakar L. et al. Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines. Clin. Exp. Allergy. 2011, v. 41, p. 1201-1220.
  6. Shekelle P.G., Woolf S.H., Eccles M. et al. J. Clinical guidelines: developing guidelines. BMJ. 1999, v. 318, p. 593-596.
  7. Bousquet J., Lockey R.F., Malling H.J. WHO, Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. J. Allergy. 1998, v. 53, p. 1-42.
  8. Wesley B.A., Calderon M.A., Casale T et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology / European Academy of Allergy and Clinical Immunology / PRACTALL consensus report. J. Allergy Clin. Immunol. 2013, v. 131, p. 1288-1296.
  9. Abramson M.J., Puy R.M., Weiner J.M. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010, v. 8, CD001186.
  10. Penagos M., Passalacqua G., Compalati E. et al. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. J. Chest. 2008, v. 133, p. 599-609.
  11. Compalati E., Braido F., Canonica G.W An update on allergen immunotherapy and asthma. Curr. Opin. Pulm. Med. 2014, v. 20, p. 109-117.
  12. Papadopoulos N.G., Arakawa H., Carlsen K.H. et al. International consensus on (ICON) pediatric asthma. J. Allergy. 2012, v. 67, p. 976-997.
  13. Calderon M.A., Cox L., Casale T.B. et al. Multiple-allergen and single- allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J. Allergy Clin. Immunol. 2012, v. 129, p. 929-934.
  14. Bousquet J., Hejjaoui A., Dhivert H. et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma. J. Allergy Clin. Immunol. 1989, v. 83, p. 797-802.
  15. Lockey R.F., Nicoara-Kasti G.L., Theodoropoulos D.S. et al. Systemic reactions and fatalities associated with allergen immunotherapy. Ann. Allergy Asthma Immunol. 2001, v. 87, p. 47-55.
  16. Bernstein D.I., Wanner M., Borish L. et al. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J. Allergy Clin. Immunol. 2004, v. 113, p. 1129-1136.
  17. Schiappoli M., Ridolo E., Senna G. et al. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. Clin. Exp. Allergy. 2009, v. 39, p. 1569-1574.
  18. Update CSM. Desensitising vaccines. Br. Med. J. 1986, v. 293, p. 948.
  19. Bousquet J., Mantzouranis E., Cruz A.A. et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on severe asthma. J. Allergy Clin. Immunol. 2010, v. 126, p. 926-938.
  20. Nielsen L., Johnsen C., Mosbech H. et al. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J. Allergy Clin. Immunol. 1996, v. 97, p. 1207-1213.
  21. Massanari M., Nelson H., Casale T. et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J. Allergy Clin. Immunol. 2010, v. 125, p. 383-389.
  22. Garcia-Robaina J.C., Sanchez I., de la Torre F. et al. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farina in a double-blind, placebo-controlled study. J. Allergy Clin. Immunol. 2006, v. 118, p. 1026-1032.
  23. Walker S.M., Durham S.R., Till S.J. et al. BSACI guidelines immunotherapy for allergic rhinitis. Clin. Exp. Allergy. 2011, v. 41, p. 1177-1200.
  24. Alvarez-Cuesta E., Beristain A. Conduite pratique de l’immu-noth_erapie. Practical management of immunotherapy. Revue Française d’Allergologie et d’Immunologie Clinique. 2003, v. 43, p. 301-309.
  25. Turkcapar N., Kinikli G., Sak S.D. et al. Specific immunotherapy-induced Sjogren’s syndrome. Rheumatol Int. 2005, v. 26, p. 182-184.
  26. Nakajima H., Ohtsuka S., Nishina T. et al. Multiple sclerosis after allergen-specific immunotherapy and influenza vaccination. J. Eur. Neurol. 2003, v. 50, p. 248-249.
  27. Maciel B.M., Morfin B.M. Specific immunotherapy - related scleroderma. Case report. Rev. Allerg. Mex. 2009, v. 56, p.135-144.
  28. Quirce S., Fernandez R.M., Losada E. et al. Recurrent pericarditis: a rare complication of allergen immunotherapy. J. Allergy. 1992, v. 47, p. 343-345.
  29. Taylor R.J. Hypersensitivity vasculitis occurring in a patient receiving immunotherapy. J. Allergy Clin. Immunol. 1991, v. 87, p. 889-890.
  30. Berbis P., Carena M.C., Auffranc J.C. et al. Cutaneo-systemic necrotizing vasculitis occurring during desensitization. J. Ann. Dermatol. Venereol. 1986, v. 113, p. 805-810.
  31. Ghoreschi K., Fischer J., Biedermann T Manifestation of rheumatoid arthritis during subcutaneous allergen-specific immunotherapy with bee venom. J. Allergy Clin. Immunol. 2012, v. 130, p. 1438-1439.
  32. Perricone C., Colafrancesco S., Mazor R.D. et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J. Autoimmun. 2013, v. 47, p. 1-16.
  33. Branco-Ferreira M., Clode M.H., Palma-Carlos A.G. Distal digital vasculitis induced by specific immunotherapy. J. Allergy. 1998, v. 53, p. 102-103.
  34. Cabrera G.E., Citera G., Gutierrez M. et al. Digital vasculitis following allergic desensitization treatment. J. Rheumatol. 1993, v. 20, p. 1970-1972.
  35. Fiorillo A., Fonacier L., Diola C. Safety of allergenic immunotherapy in systemic lupus erythematosus. J. Allergy Clin. Immunol. 2006, v. 117 (2 Suppl), p. 264.
  36. Golden D.B., Moffitt J., Nicklas R.A. et al. Stinging insect hypersensitivity: a practice parameter update. J. Allergy Clin. Immunol. 2011, v. 127, p. 852-854.
  37. Palomares O., Yaman G., Azkur A.K. et al. Role of T-regulatory cells in immune regulation of allergic diseases. Eur. J. Immunol. 2010, v. 40, p. 1-9.
  38. Shereff R.H., Harwell W., Lieberman P. et.al. Effect of beta adrenergic stimulation and blockade on immediate hypersensitivity skin test reactions. J. Allergy Clin. Immunol. 1973, v. 52, p. 328-333.
  39. Hiatt W.R., Wolfel E.E., Stoll S. et al. Beta-2 adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol. Clin. Pharmacol. Ther. 1985, v. 37, p. 2-6.
  40. Assem E.S., Schild H.O. Antagonism by beta-adrenoceptor blocking agents of the antianaphylactic effect of isoprenaline. Br. J. Pharmacol. 1971, v. 42, p. 620-630.
  41. Matsumura Y., Tan E.M., Vaughan J.H. Hypersensitivity to histamine and systemic anaphylaxis in mice with pharmacologic beta adrenergic blockade: protection by nucleotides. J. Allergy Clin. Immunol. 1976, v. 58, p. 387-394.
  42. Nisam M.R., Zbinden A., Chesrown S. et al. Distribution and pharmacological release of histamine in canine lung in vivo. J. Appl. Physiol. 1978, v. 44, p. 455-463.
  43. Jacobs R.L., Rake G.W., Fournier D.C. et al. Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade. J. Allergy Clin. Immunol. 1981, v. 68, p. 125-127.
  44. Newman B.R., Schultz L.K. Epinephrineresistant anaphylaxis in a patient taking propranolol hydrochloride. Ann. Allergy. 1981, v. 47, p. 35-37.
  45. Kivity S., Yarchovsky J. Relapsing anaphylaxis to bee sting in a patient treated with beta-blocker and Ca blocker. J. Allergy Clin. Immunol. 1990, v. 85, p. 669-670.
  46. Toogood J.H. Beta-blocker therapy and the risk of anaphylaxis. CMAJ. 1987, v. 137, p. 587-588.
  47. Cleaveland C.R., Rangno R.E., Shand D.G. A standardized isoproterenol sensitivity test. The effects of sinus arrhythmia, atropine, and propranolol. Arch. Intern. Med. 1972, v. 130, p. 47-52.
  48. Lang D.M. Anaphylactoid and anaphylactic reactions. Hazards of beta-blockers. Drug Saf. 1995, v. 12, p. 299-304.
  49. Lee S., Hess E.P., Nestler D.M. et al. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. J. Allergy Clin. Immunol. 2013, v. 131, p. 1103-1108.
  50. Sasvary T., Muller U. Fatalities from insect stings in Switzerland 1978 to 1987. Schweiz Med. Wochenschr. 1994, v. 124, p. 1887-1894.
  51. Bonifazi F., Jutel M., Bilo B.M. et al. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. J. Allergy. 2005, v. 60, p. 1459-1470.
  52. Tunon-de-Lara J.M., Villanueva P., Marcos M. et al. ACE inhibitors and anaphylactoid reactions during venom immunotherapy. J. Lancet. 1992, v. 340, p. 908.
  53. Ober A.I., MacLean J.A., Hannaway P.J. Lifethreatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor. J. Allergy Clin. Immunol. 2003, v. 112, p. 1008-1009.
  54. Hermann K., Ring J. The renin angiotensin system and hymenoptera venom anaphylaxis. Clin. Exp. Allergy. 1993, v. 23, p. 762-769.
  55. Hermann K., von Tschirschnitz M., Ebner von Eschenbach C. et al. Histamine, tryptase, norepinephrine, angiotensinogen, angiotensin-converting enzyme, angiotensin I and II in plasma of patients with hymenoptera venom anaphylaxis. Int. Arch Allergy Immunol. 1994, v. 104, p. 379-384.
  56. Hermann K., Ring J. The renin-angiotensin system in patients with repeated anaphylactic reactions during hymenoptera venom hyposensitization and sting challenge. Int. Arch Allergy Immunol. 1997, v. 112, p. 251-256.
  57. Rueff F., Przybilla B., Bilo M.B. et al. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J. Allergy Clin. Immunol. 2010, v. 126, p. 105-115.
  58. Stoevesandt J., Hain J., Stolze I. et al. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase. Clin. Exp. Allergy. 2014, v. 44, p. 747-755.
  59. Rueff F., Vos B., Elberink J.O. et al. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. J. Clin. Exp. Allergy. 2014, v. 44, p. 736-746.
  60. Livingston M.G., Livingston H.M. Monoamine oxidase inhibitors. An update on drug interactions. J. Drug Saf. 1996, v. 14, p. 219-227.
  61. Dawson J.K., Earnshaw S.M., Graham C.S. Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. J. Accid. Emerg. Med. 1995, v. 12, p. 49-51.
  62. Linneberg A., Jacobsen R.K., Jespersen L. et al. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J. Allergy Clin. Immunol. 2012, v. 129, p. 413-419.
  63. Moriset M., Moneret-Vautrin D.A., Guenard L. et al. Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. A randomized study in 60 children with cow’s milk allergy and 90 children with egg allergy. Eur. Ann. Allergy Clin. Immunol. 2007, v. 39, p. 12-19.
  64. Staden U., Rolink-Werning Haus C., Brewer F. et al. Specific oral tolerance induction in food allergy in children: efficacy and clinical pattern of reaction. J. Allergy. 2007, v. 62, p. 1261-1269.
  65. Barbi E., Longo G., Berti I. et al. Adverse effects during specific oral induction: in hospital «rush» phase. Eur. Ann. Allergy Clin. Immunol. 2012, v. 44, p. 18-25.
  66. Penagos M., Compalati E., Tarantini F. et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a metaanalysis of randomized, placebo-controlled, double-blind trials. Ann. Allergy Asthma Immunol. 2006, v. 97, p. 141-148.
  67. Rodriguez-Santos O. Sublingual immunotherapy in allergic rhinitis and asthma in 2-5-year-old children sensitized to mites. Rev. Allerg. Mex. 2008, v. 55, p. 71-75.
  68. Rienzo V.D., Minelli M., Musarra A. et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin. Exp. Allergy. 2005, v. 35, p. 560-564.
  69. Agostinis F., Tellarini L., Canonica G.W et al. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. J. Allergy. 2005, v. 60, p. 133-134.
  70. Fiocchi A., Pajno G., La Grutta S. et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann. Allergy Asthma Immunol. 2005, v. 95, p. 254-258.
  71. Martinez-Canavate A., Tabar A.I., Eseverri J.L. et al. An epidemiological survey of hymenoptera venom allergy in the Spanish paediatric population. J. Allergol. Immunopathol. (Madr.). 2010, v. 38, p. 259-262.
  72. Valentine M.D., Schuberth K.C., Kagey-Sobotka A. et al. The value of immunotherapy with venom in children with allergy to insect stings. N. Engl. J. Med. 1990, v. 323, p. 1601-1603.
  73. Webster W.S., Freeman J.A.D. Prescription drugs and pregnancy. Expert Opin. Pharmacother. 2003, v. 4, p. 949-961.
  74. Simons F.E., Schatz M.J. Anaphylaxis during pregnancy. J. Allergy Clin. Immunol. 2012, v. 130, p. 597-606.
  75. Helbling A., Muller U.R., Hausmann O. Uterine contractions are known side effects of venom immunotherapy. J. Investig. Allergol Clin. Immunol. 2011, v. 21, p. 330.
  76. Cadavid A.P., Bannenberg G.L., Arck P.C. et al. Prevention and treatment of allergic asthma in pregnancy: from conventional drugs to new therapeutical approaches. Curr. Pharm. Biotechnol. 2011, v. 12, p. 758-764.
  77. Gani F., Braida A., Lombardi C. et al. Rhinitis in pregnancy. Eur. Ann. Allergy Clin. Immunol. 2003, v. 35, p. 306-313.
  78. Demoly P., Piette V., Daures J.P. Treatment of allergic rhinitis during pregnancy. J. Drugs. 2003, v. 16, p. 1813-1820.
  79. Schwartz H.J., Golden D.B., Lockey R.F. Venom immunotherapy in the Hymenoptera- allergic pregnant patient. J. Allergy Clin. Immunol. 1990, v. 85, p. 709-712.
  80. Shaikh W.A., Shaikh S.W A prospective study on the safety of sublingual immunotherapy in pregnancy. J. Allergy. 2012, v. 67, p. 741-743.
  81. Metzger W.J., Turner E., Patterson R. The safety of immunotherapy during pregnancy. J. Allergy Clin. Immunol. 1978, v. 61, p. 268-272.
  82. Shaikh W.A. A retrospective study on the safety of immunotherapy in pregnancy. Clin. Exp. Allergy. 1993, v. 23, p. 857-860.
  83. Marshal G.D. Jr. Allergen immunotherapy in HIV-infected patients. Immunol. Allergy Clin. North Am. 1997, v. 2, p. 303-317.
  84. Marshal G.D. Jr. AIDS, HIV-positive patients, and allergies. Allergy Asthma Proc. 1999, v. 20, p. 301-304.
  85. From the Centers for Disease Control and Prevention. 1993. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA. 1993, v. 269, p. 729-730.
  86. Marcoval J., Moreno A., Mana Titel J. Subcutaneous sarcoidosis localized to sites of previous desensitizing injections. Clin. Exp. Dermatol. 2007, v. 33, p. 132-134.
  87. Schulze J., Rose M., Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. J. Allergy. 2007, v. 62, p. 963-964.
  88. Kontou-Fili K., Filis C.I. Prolonged high dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. J. Allergy. 2009, v. 64, p. 1384-1385.
  89. Casale T.B., Busse W.W., Kline J.N. et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. 2006, v. 117, p. 134-140.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Pharmarus Print Media, 2017

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».